Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft‐versus‐host disease. (1st November 2017) - Hurabielle, C.; Sicre de Fontbrune, F.; Moins‐Teisserenc, H.; Robin, M.; Jachiet, M.; Coman, T.; Dhedin, N.; Cassius, C.; Chasset, F.; de Masson, A.; Michonneau, D.; Bagot, M.; et al.